Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Revised criteria for the early diagnosis of diabetic nephropathy].
Inomat S, Haneda M, Moriya T, Katayama S, Iwamoto Y, Sakai H, Tomino Y, Matsuo S, Asano Y, Makino H; Diabetic Nephropha Committee. Inomat S, et al. Among authors: moriya t. Nihon Jinzo Gakkai Shi. 2005;47(7):767-9. Nihon Jinzo Gakkai Shi. 2005. PMID: 16296406 Japanese.
The telmisartan renoprotective study from incipient nephropathy to overt nephropathy--rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study.
Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S. Makino H, et al. Among authors: moriya t. J Int Med Res. 2005 Nov-Dec;33(6):677-86. doi: 10.1177/147323000503300610. J Int Med Res. 2005. PMID: 16372586 Free article. Clinical Trial.
Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study.
Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S; INNOVATION Study Group. Makino H, et al. Among authors: moriya t. Hypertens Res. 2008 Apr;31(4):657-64. doi: 10.1291/hypres.31.657. Hypertens Res. 2008. PMID: 18633177 Clinical Trial.
Low transition rate from normo- and low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals: the Japan Diabetes Complications Study (JDCS).
Katayama S, Moriya T, Tanaka S, Tanaka S, Yajima Y, Sone H, Iimuro S, Ohashi Y, Akanuma Y, Yamada N; Japan Diabetes Complications Study Group. Katayama S, et al. Among authors: moriya t. Diabetologia. 2011 May;54(5):1025-31. doi: 10.1007/s00125-010-2025-0. Epub 2011 Feb 1. Diabetologia. 2011. PMID: 21286682 Free PMC article.
[Cystatin C].
Okizaki S, Moriya T. Okizaki S, et al. Among authors: moriya t. Nihon Rinsho. 2010 Nov;68 Suppl 9:419-25. Nihon Rinsho. 2010. PMID: 21667497 Review. Japanese. No abstract available.
Comparison of various lipid variables as predictors of coronary heart disease in Japanese men and women with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study.
Sone H, Tanaka S, Tanaka S, Iimuro S, Ishibashi S, Oikawa S, Shimano H, Katayama S, Ohashi Y, Akanuma Y, Yamada N; Japan Diabetes Complications Study Group. Sone H, et al. Diabetes Care. 2012 May;35(5):1150-7. doi: 10.2337/dc11-1412. Epub 2012 Feb 14. Diabetes Care. 2012. PMID: 22338107 Free PMC article.
Diabetic retinopathy and microalbuminuria can predict macroalbuminuria and renal function decline in Japanese type 2 diabetic patients: Japan Diabetes Complications Study.
Moriya T, Tanaka S, Kawasaki R, Ohashi Y, Akanuma Y, Yamada N, Sone H, Yamashita H, Katayama S; Japan Diabetes Complications Study Group. Moriya T, et al. Diabetes Care. 2013 Sep;36(9):2803-9. doi: 10.2337/dc12-2327. Epub 2013 Apr 25. Diabetes Care. 2013. PMID: 23620478 Free PMC article. Clinical Trial.
1,106 results